Last reviewed · How we verify
Razoxin (RAZOXANE)
Razoxin (generic name: RAZOXANE) is a drug. It is currently in Phase 2 development for Doxorubicin Induced Cardiomyopathy, Extravasation Injury from Anthracycline Injection.
Razoxin works by chelating iron and preventing the formation of free radicals that damage heart tissue.
Razoxin is a small molecule with the synonyms ICI 59118, ICI-59118, ICRF 159, ICRF-159, NSC-129943, and RAZOXANE. It is being studied in clinical trials for various types of cancer, including Ewing's Sarcoma, Neuroblastoma, Rhabdomyosarcoma, Hepatoblastoma, Sarcoma, and Soft Tissue Sarcoma.
-
Baseline phase 2 → approval rate
+15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2031–2034 | — |
| EMA | EU | 2032–2035 | +0.7 yr |
| MHRA | GB | 2032–2035 | +0.7 yr |
| Health Canada | CA | 2032–2036 | +0.9 yr |
| TGA | AU | 2032–2036 | +1.2 yr |
| PMDA | JP | 2032–2036 | +1.5 yr |
| NMPA | CN | 2033–2037 | +2.3 yr |
| MFDS | KR | 2032–2036 | +1.4 yr |
| CDSCO | IN | 2032–2037 | +1.8 yr |
| ANVISA | BR | 2033–2037 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | RAZOXANE |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
Think of Razoxin like a magnet that attaches to iron and prevents it from causing harm. When anthracycline chemotherapy agents are used, they can release iron that damages the heart. Razoxin helps to bind to this iron and prevent it from causing damage.
Approved indications
- Doxorubicin Induced Cardiomyopathy
- Extravasation Injury from Anthracycline Injection
Common side effects
Key clinical trials
- Risk-Based Therapy in Treating Younger Patients With Newly Diagnosed Liver Cancer (PHASE3)
- Venetoclax Basket Trial for High Risk Hematologic Malignancies (PHASE1)
- Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL) (PHASE3)
- Testing a Standardized Approach to Surgery and Chemotherapy for Type I Pleuropulmonary Blastoma or the Addition of an Anti-cancer Drug, Topotecan, to the Usual Treatment for Types II and III Pleuropulmonary Blastoma (PHASE3)
- A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations (PHASE3)
- Pediatric Classical Hodgkin Lymphoma Consortium Study: cHOD17 (PHASE2)
- Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (PHASE3)
- 05-001: Treatment of Acute Lymphoblastic Leukemia in Children (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Razoxin CI brief — competitive landscape report
- Razoxin updates RSS · CI watch RSS
Frequently asked questions about Razoxin
What is Razoxin?
How does Razoxin work?
What is Razoxin used for?
What is the generic name of Razoxin?
What development phase is Razoxin in?
Related
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Doxorubicin Induced Cardiomyopathy
- Indication: Drugs for Extravasation Injury from Anthracycline Injection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing